PCI Biotech Holding ASA

OB:PCIB Stock Report

Market Cap: NOK 50.9m

PCI Biotech Holding Management

Management criteria checks 2/4

We currently do not have sufficient information about the CEO.

Key information

Ronny Skuggedal

Chief executive officer

NOK 2.4m

Total compensation

CEO salary percentage82.8%
CEO tenure11.3yrs
CEO ownership0.1%
Management average tenureno data
Board average tenure8.7yrs

Recent management updates

Recent updates

We're Keeping An Eye On PCI Biotech Holding's (OB:PCIB) Cash Burn Rate

Aug 05
We're Keeping An Eye On PCI Biotech Holding's (OB:PCIB) Cash Burn Rate

We Think PCI Biotech Holding (OB:PCIB) Needs To Drive Business Growth Carefully

Apr 21
We Think PCI Biotech Holding (OB:PCIB) Needs To Drive Business Growth Carefully

We're Hopeful That PCI Biotech Holding (OB:PCIB) Will Use Its Cash Wisely

Dec 16
We're Hopeful That PCI Biotech Holding (OB:PCIB) Will Use Its Cash Wisely

We're Not Very Worried About PCI Biotech Holding's (OB:PCIB) Cash Burn Rate

Apr 09
We're Not Very Worried About PCI Biotech Holding's (OB:PCIB) Cash Burn Rate

What Type Of Shareholders Own The Most Number of PCI Biotech Holding ASA (OB:PCIB) Shares?

Feb 15
What Type Of Shareholders Own The Most Number of PCI Biotech Holding ASA (OB:PCIB) Shares?

PCI Biotech Holding (OB:PCIB) Is In A Good Position To Deliver On Growth Plans

Dec 22
PCI Biotech Holding (OB:PCIB) Is In A Good Position To Deliver On Growth Plans

CEO Compensation Analysis

How has Ronny Skuggedal's remuneration changed compared to PCI Biotech Holding's earnings?
DateTotal CompensationSalaryCompany Earnings
Jun 30 2024n/an/a

-NOK 16m

Mar 31 2024n/an/a

-NOK 18m

Dec 31 2023NOK 2mNOK 2m

-NOK 20m

Sep 30 2023n/an/a

-NOK 23m

Jun 30 2023n/an/a

-NOK 29m

Mar 31 2023n/an/a

-NOK 38m

Dec 31 2022NOK 2mNOK 2m

-NOK 55m

Sep 30 2022n/an/a

-NOK 73m

Jun 30 2022n/an/a

-NOK 84m

Mar 31 2022n/an/a

-NOK 88m

Dec 31 2021NOK 2mNOK 2m

-NOK 88m

Sep 30 2021n/an/a

-NOK 90m

Jun 30 2021n/an/a

-NOK 90m

Mar 31 2021n/an/a

-NOK 100m

Dec 31 2020NOK 3mNOK 1m

-NOK 72m

Sep 30 2020n/an/a

-NOK 71m

Jun 30 2020n/an/a

-NOK 64m

Mar 31 2020n/an/a

-NOK 61m

Dec 31 2019NOK 2mNOK 1m

-NOK 89m

Sep 30 2019n/an/a

-NOK 68m

Jun 30 2019n/an/a

-NOK 62m

Mar 31 2019n/an/a

-NOK 43m

Dec 31 2018NOK 2mNOK 1m

-NOK 35m

Compensation vs Market: Ronny's total compensation ($USD214.81K) is about average for companies of similar size in the Norwegian market ($USD283.61K).

Compensation vs Earnings: Ronny's compensation has increased whilst the company is unprofitable.

CEO

Ronny Skuggedal (48 yo)

11.3yrs

Tenure

NOK 2,443,000

Compensation

Mr. Ronny Skuggedal has been the Chief Financial Officer at PCI Biotech Holding ASA and PCI Biotech AS since joining in October 2013. He serves as Chief Executive Officer at PCI Biotech Holding ASA since S...

Board Members

NamePositionTenureCompensationOwnership
Hans Bohn
Independent Chairman9.7yrsNOK 395.00k0.33%
NOK 168.7k
Lars Viksmoen
Independent Director8.7yrsNOK 260.00k0.035%
NOK 17.7k
Hilde Furberg
Independent Director5.7yrsNOK 260.00kno data

8.7yrs

Average Tenure

69yo

Average Age

Experienced Board: PCIB's board of directors are considered experienced (8.7 years average tenure).

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/01/02 04:01
End of Day Share Price 2025/01/02 00:00
Earnings2024/06/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

PCI Biotech Holding ASA is covered by 1 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Hans BohnBeringer Finance AB